摘要
Context: Interest exits in whether TNF-alpha antagonists increase the risk of breast cancer and total malignancies in patients with rheumatoid arthritis (RA). Objectives: To analyze the risk of malignancies, especially breast cancer, in patients with RA enrolled in randomized control trials (RCTs). Methods: A systematic literature search for RCTs from 1 January 1998 to 1 July 2013 from online databases, such as PubMed, WILEY, EMBASE, ISI web of knowledge and Cochrane Library was conducted. Studies included RCTs that compared the safety of at least one dose of the five TNF-alpha antagonists with placebo or methotrexate (MTX) (or TNF-alpha antagonists plus MTX vs placebo plus MTX) in RA patients for more than 24 weeks and imported all the references into document management software EndNotex6. Two independent reviewers selected studies and extracted the data about study design, patients' characteristics and the type, number of all malignancies. Results: 28 RCTs from 34 records with 11,741 patients were analyzed. Of the total, 97 developed at least one malignancy during the double-blind trials, and breast cancer was observed in 17 patients (17.5% of total malignancies). However, there was no statistically significant increased risk observed in either the per protocol (PP) model (OR 0.65, 95% CI [0.22, 1.93]) or the modified intention to treat (mITT) model (OR 0.75, 95% CI [0.25, 2.21]). There were also no significant trend for increased risk of total malignancies on anti-TNF-alpha therapy administered at approved doses in either model (OR, 1.06, 95% CI [0.64, 1.75], and OR, 1.30, 95% CI [0.80, 2.14], respectively). As to the two models, modified intention to treat model analysis led to higher estimation than per protocol model analysis. Conclusions: This study did not find a significantly increased risk of breast cancer and total malignancies in adults RA patients treated with TNF-alpha antagonists at approved doses. However, it cannot be ignored that more patients developed malignancies with TNF-alpha antagonists therapy compared with patients with placebo or MTX, in spite of the lack of statistical significance, so that more strict clinical trials and long-term follow-up are needed, and both mITT and PP analyses should be used in such safety analyses.
| 源语言 | 英语 |
|---|---|
| 页(从-至) | 3403-3410 |
| 页数 | 8 |
| 期刊 | Asian Pacific Journal of Cancer Prevention |
| 卷 | 15 |
| 期 | 8 |
| DOI | |
| 出版状态 | 已出版 - 1月 2014 |
基金资助
We appreciate the financial support by the National Natural Science Funds (no. 30901308), Wuhan key scientific and technological project (2014060101010045), the Dawn Project for Young Scientists of Wuhan City (no. 20105023106), and the Hubei Province Natural Science Funds of (no. 2013CFB233 and no. 2013CFB235). In addition, We deeply thank to all the people who gave us good suggestions and help.
联合国可持续发展目标
此成果有助于实现下列可持续发展目标:
-
可持续发展目标 3 良好健康与福祉
关键词
- TNF-alpha antagonist therapy
- rheumatoid arthritis
- breast cancer
- malignancies
- meta analysis
收录
- SCIE
- Scopus
学术指纹
探究 'Risk of Breast Cancer and Total Malignancies in Rheumatoid Arthritis Patients Undergoing TNF-α Antagonist Therapy: a Meta-analysis of Randomized Control Trials' 的科研主题。它们共同构成独一无二的学术指纹。引用此
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver